3: Vitamin D status and cystic fibrosis –related diabetes: A retrospective chart review

Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Posters Source Type: research

Related Links:

Environ Sci Pollut Res Int. 2022 Jan 15. doi: 10.1007/s11356-022-18534-2. Online ahead of print.ABSTRACTDiabetes mellitus (DM) is a worldwide ailment which leads to chronic complications like cardiac disorders, renal perturbations, limb amputation and blindness. Type one diabetes (T1DM), Type two diabetes (T2DM), Another types of diabetes, such as genetic errors in function of β-cell and action of insulin, cystic fibrosis, chemical-instigated diabetes or following tissue transplantation), and pregnancy DM (GDM). In response to nutritional ingestion, the gut may release a pancreatic stimulant that affects carbohydrate ...
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Source Type: research
Pharmacol Rev. 2022 Jan;74(1):48-118. doi: 10.1124/pharmrev.120.000108.ABSTRACTThe purpose of this review is to summarize essential pharmacological, pharmaceutical, and clinical aspects in the field of orally inhaled therapies that may help scientists seeking to develop new products. After general comments on the rationale for inhaled therapies for respiratory disease, the focus is on products approved approximately over the last half a century. The organization of these sections reflects the key pharmacological categories. Products for asthma and chronic obstructive pulmonary disease include β -2 receptor agonists, m...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Ischemic heart disease is rarely reported in people with cystic fibrosis (PwCF) despite multiple potential risk factors. Here we report two cases of ST elevation myocardial infarction (STEMI), both in young women with cystic fibrosis (CF) and cystic fibrosis related diabetes (CFRD). These cases illustrate the importance of considering myocardial injury/infarction in the differential diagnosis of patients with CF and chest pain or shortness of breath, and addressing the growing risk of cardiovascular disease (CVD).
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research
CF clinical teams have borne witness to the population increases in CF and ageing CF population predicted across Europe [1]. This trend is set to continue with the advent of the highly effective CFTR modulators and CF teams are honing skills in managing diabetes, obesity and dyslipidaemia.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Correspondence Source Type: research
AbstractPurposeTo describe the clinical course of COVID-19 in patients with cystic fibrosis (CF) and to identify risk factors for severe COVID-19.MethodsWe conducted a prospective study within the Italian CF Society. CF centers collected baseline and follow-up data of patients with virologically confirmed SARS-CoV-2 infection between March 2020 and June 2021. Odds ratios (ORs) for severe SARS-CoV-2 (as defined by hospital admission) were estimated by logistic regression models.ResultsThe study included 236 patients with positive molecular test for SARS-CoV-2. Six patients died, 43 patients were admitted to hospital, 4 admi...
Source: Infection - Category: Infectious Diseases Source Type: research
In recent years, improving treatments for cystic fibrosis (CF) have dramatically enhanced the longevity and quality of life for people with CF. The pathogenesis of CF has been well characterised and has been directly linked to a dysfunctional chloride channel termed the cystic fibrosis transmembrane conductance regulator (CFTR), which is predominately found in epithelial tissue layers [1]. Until recently, most treatments for CF have focused on supportive care including enhanced airway clearance therapies, improved nutritional support, management of CF sequelae such as CF-related diabetes and liver disease, and/or treatment...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
CONCLUSIONS: CGM measures of hyperglycemia and glycemic variability are superior to HbA1c in distinguishing those with and without CFRD. CGM-derived AG is strongly correlated with HbA1c in adults with CF, with a similar relationship to other diabetes populations. Future studies are needed to investigate CGM as a diagnostic and screening tool for CFRD.PMID:34850006 | DOI:10.1210/clinem/dgab857
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research
CONCLUSIONS: No studies were included in the review, indicating that there is currently insufficient evidence to determine the impact of insulin therapy guided by CGMS compared to insulin therapy guided by other forms of glucose data collection on the lives of people with CFRD, nor on potential adverse effects of continuous glucose monitoring in this context. Randomised controlled studies are needed to generate evidence on the efficacy and safety of continuous glucose monitoring in people with CFRD. There is one relevant ongoing study that may be eligible for inclusion in a future update of this Cochrane Review, and whose ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
uma This paper presents sensor nanotechnologies that can be used for the skin-based gas “smelling” of disease. Skin testing may provide rapid and reliable results, using specific “fingerprints” or unique patterns for a variety of diseases and conditions. These can include metabolic diseases, such as diabetes and cholesterol-induced heart disease; neurological diseases, such as Alzheimer’s and Parkinson’s; quality of life conditions, such as obesity and sleep apnea; pulmonary diseases, such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease; gastrointestinal tract d...
Source: Sensors - Category: Biotechnology Authors: Tags: Perspective Source Type: research
Conclusion: In the current research study we demonstrated our methodology to create apremilast powder and produce apremilast aerosol droplets with different nebulisers and residual cups.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Brief Report Source Type: research
More News: Cystic Fibrosis | Diabetes | Endocrinology | Respiratory Medicine | Vitamin D | Vitamins